Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKTR-102 + Cetuximab in Solid Tumors and Colorectal Cancer
NCT00598975Phase 2Completed
- Sponsor
- Nektar Therapeutics
- Start
- Feb 2008
- Primary completion
- May 2009
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of etirinotecan pegol in solid tumor, colorectal cancer (CRC), sponsored by Nektar Therapeutics. Started Feb 2008; status: completed.
02
Drugs
etirinotecan pegol
03
Conditions
solid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00598975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00598975.